Role of surgical staging and adjuvant treatment in uterine serous carcinoma

被引:0
作者
Frey, M. K. [1 ]
Bashir, S. [1 ]
Ward, N. M. [1 ]
Hensel, K. J. [2 ]
Caputo, T. A. [1 ]
Holcomb, K. M. [1 ]
Baergen, R. [3 ]
Gupta, D. [1 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Gynecol Oncol, Dept Obstet & Gynecol, New York, NY USA
[2] Columbia Univ, Dept Pediat, Div Infect Dis, Med Ctr, New York, NY 10027 USA
[3] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol, New York, NY USA
关键词
Uterine serous carcinoma; Surgical staging; Adjuvant therapy; PAPILLARY; RADIATION; SURVIVAL; CHEMOTHERAPY; ENDOMETRIUM; UPSC;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of investigation: This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence. Materials and Methods: Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared. Results: Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043). Conclusion: In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.
引用
收藏
页码:453 / 456
页数:4
相关论文
共 26 条
  • [1] [Anonymous], INT J GYNAECOL OBSTE
  • [2] Extended surgical staging for uterine papillary serous carcinoma: Survival outcome of locoregional (Stage I-III) disease
    Bristow, RE
    Asrari, F
    Trimble, EL
    Montz, FJ
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 81 (02) : 279 - 286
  • [3] THERAPEUTIC APPROACHES TO UTERINE PAPILLARY SEROUS CARCINOMA - A PRELIMINARY-REPORT
    CHRISTMAN, JE
    KAPP, DS
    HENDRICKSON, MR
    HOWES, AE
    BALLON, SC
    [J]. GYNECOLOGIC ONCOLOGY, 1987, 26 (02) : 228 - 235
  • [4] Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma
    Cirisano, FD
    Robboy, SJ
    Dodge, RK
    Bentley, RC
    Krigman, HR
    Synan, IS
    Soper, JT
    Clarke-Pearson, DL
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 74 (03) : 385 - 394
  • [5] Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma
    Einstein, Mark H.
    Frimer, Marina
    Kuo, Dennis Y. -S.
    Reimers, Laura L.
    Mehta, Keyur
    Mutyala, Subhakar
    Huang, Gloria S.
    Hou, June Y.
    Goldberg, Gary L.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 124 (01) : 21 - 25
  • [6] Uterine papillary serous carcinoma: epidemiology, pathogenesis and management
    Fader, Amanda Nickles
    Boruta, David
    Olawaiye, Alexander B.
    Gehrig, Paola A.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 21 - 29
  • [7] FRANK AH, 1991, CANCER, V68, P1516, DOI 10.1002/1097-0142(19911001)68:7<1516::AID-CNCR2820680709>3.0.CO
  • [8] 2-X
  • [9] Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
  • [10] GITSCH G, 1995, CANCER-AM CANCER SOC, V75, P2239, DOI 10.1002/1097-0142(19950501)75:9<2239::AID-CNCR2820750908>3.0.CO